Last reviewed · How we verify
Intravenous levetiracetam — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Intravenous levetiracetam (Intravenous levetiracetam) — Muhammad Aamir Latif.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intravenous levetiracetam TARGET | Intravenous levetiracetam | Muhammad Aamir Latif | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intravenous levetiracetam CI watch — RSS
- Intravenous levetiracetam CI watch — Atom
- Intravenous levetiracetam CI watch — JSON
- Intravenous levetiracetam alone — RSS
Cite this brief
Drug Landscape (2026). Intravenous levetiracetam — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-levetiracetam. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab